CASTLE BIOSCIENCES, INC. Increase (Decrease) in Contract with Customer, Liability
CASTLE BIOSCIENCES, INC. (CSTL) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-02-28
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was $0.00.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was $0.00.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was -$3.00M.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was -$3.18M.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2021 was -$8.35M, a 200.00% decline from fiscal 2020.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2020 was $8.35M.
- CASTLE BIOSCIENCES, INC. increase (decrease) in contract with customer, liability for fiscal 2019 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$6.18M derived: sum of 2 quarters · filed 2023-02-28 | -$8.35M 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$3.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$5.35M 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | -$2.17M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $8.35M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $8.35M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $8.35M 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 10-K · filed 2021-03-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |